This site is intended for healthcare professionals residing in Canada.

Visit Pfizer Academy
Search

Menu

Close

Sign InLog Out
  • EN
ProductsTherapy AreasExplore ContentExplore
ContentGo to Explore ContentEventsMaterialsVideosPatient SupportContact
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Français

Menu

Close

AboutAboutSerotypesMechanism of ActionCAPiTA: Prevnar 13 Efficacy profileImmunogenicity profileSafety profilePatient profilesDosingDosingDosingPneumococcal diseasePneumococcal diseasePneumococcal diseasePneumococcal serotypesRisk factorsRecommendationsRecommendationsRecommendationsResourcesResourcesMaterialsVideos
Important Safety InformationProduct Monograph
Pneumococcal serotypes
Distribution of serotypes in Canada*
Invasive S. pneumoniae serotypes, percentage of isolates 20191*
Serotypes Percentage of isolates (%)
3 11.5
4 7.1
6A 2
6B 2
7F 3.2
9V 1.3
14 0.3
18C 0.4
19A 4.2
19F 2
23F 0.1
8 6
10A 1.9
11A 2.7
12F 4
15B/C 2.7
22F 9.8
33F 4
9N 6.9
17F 1
20 3.6
6D 0.2
6C 1.9
7B 0.1
7C 1.2
9L 0.1
9V 1.3
10B 0.1
10F 0.1
12A 0.1
13 0.2
15A 4.4
16F 3
17A 0.1
18A 0.1
21 0.3
22A 0.1
23A 3.7
23B 3.2
24F 0.5
28A 0.2
29 0.2
31 1.3
34 1
35B 2.2
35F 1.5
38 0.7
Adapted from the National laboratory surveillance of invasive streptococcal disease in Canada – Annual summary 2019Prevnar 13 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23FPrevnar 20 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33FSerotypes that were not detected include: 1, 2, 5, 7A, 7B, 9A, 11B, 11C, 11D, 12B, 18F, 24, 24A, 24B, 25A, 27, 32A, 33A, 33B, 33C, 35A, 35C, 37, 42
  • The serotypes included in Prevnar 13 accounted for 31% of invasive pneumococcal disease cases, while the serotypes included in Prevnar 20 accounted for 62%.1-3
  • Prevnar 20-related serotypes 11A and 22F, and non-vaccine serotypes 6C and 15A were more common in adults 65 years and older, in Canada from 2011–2015.4
  • Of the 90 identified serotypes, those included in Prevnar 20 have been associated with higher case-fatality rates and mortality, antibiotic resistance, meningitis and outbreaks.5
A study from the National laboratory surveillance of invasive streptococcal disease in Canada examining the serotype distribution of 3,673 isolates causing invasive pneumococcal disease from 2015 to 2019.References:Public Health Agency of Canada. National laboratory surveillance of invasive streptococcal disease in Canada – Annual Summary 2019.Demczuk WHB, et al. Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010–2016. Vaccine. 2018;31(25):4701–4707.Demczuk WHB, et al. Supplemental material for “Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010–2016.” Vaccine. 2018;31(25):4701–4707.Golden AR, et al. Molecular characterization of predominant Streptococcus pneumonia serotypes causing invasive infections in Canada: the SAVE study, 2011–15. J Antimicrob Chemother. 2018:73(suppl 7):vii20–vii31.Prevnar 20 Product Monograph. Pfizer Canada ULC. 2022. NEXT

Risk Factor

 Visit page Loading
PP-PNR-CAN-0067-EN. April 2023

To report an adverse event, please call 1-866-723-7111

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out

© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.

PP-UNP-CAN-0145-EN
You are now leaving Pfizerpro.ca website
Links to other sites are provided as a convenience to the viewer, and should not be taken as an endorsement of the sites or an association with their owners. Pfizer Canada accepts no responsibility for the content of linked sites.
You are now leaving the PfizerPro Portal.
You are about to view resources made available by Pfizer Academy. 
These resources include learning programs and upcoming events. By selecting Go to link below, you acknowledge and certify that you are a Canadian Healthcare Professional.
PP-UNP-CAN-0013 EN